Eli Lilly announced readiness to file for FDA approval of orforglipron, an oral GLP-1 receptor agonist shown in a Phase 3 trial to significantly reduce body weight and improve glycemic control in patients with obesity and type 2 diabetes. The trial demonstrated up to 11% weight loss over 72 weeks and substantial A1C reductions. Despite promising outcomes, concerns about tolerability emerged due to higher dropout rates attributed to side effects compared to injectable competitors like Novo Nordisk’s Wegovy. Lilly's orforglipron now competes directly in a burgeoning market for oral obesity therapies, trailing Novo by several months in regulatory filing.